Overview

Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device development projects. The book provides detailed information on the historical developments of migraine pain management, druggable targets, drugs action mechanisms, drugs for acute treatment and preventive care of patients, administration routes, and alternative treatments. This is the ideal reference for academic researchers interested in anti-migraine pharmacology. It will also be a perfect reference for physicians and care professionals involved in the well-being of migraine patients.

Full Product Details

Author:   Stephen B. Shrewsbury (Formerly Impel Pharmaceuticals, USA)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
ISBN:  

9780443247057

ISBN 10:   0443247056
Pages:   500
Publication Date:   01 November 2024
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Forthcoming
Availability:   Not yet available  
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Table of Contents

"Part I – Foundations and historical development on Migraine Pain Management 1. Introduction 2. Neuroanatomy 3. Historical overview of drug development and therapeutics 4. Alternative therapy development 5. Comorbidities and their impact on therapies 6. Not all Migraine attacks are the same 7. The case for nasal delivery Part II – Druggable targets 8. CGRP 9. PACAP 10. Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists 11. Src family kinases (SFK) 12. Delta opioid receptor system 13. Piezo channels in peripheral trigeminal nociception 14. TRPM8 antagonists Part IIIa – Drugs – Acute Management 15. Simple analgesics 16. Opioids 17. Ergots 18. Triptans 19. Lasmiditan (and the ditan class) 20. Timolol 21. Rimegepant 22. Combination therapies Part IIIb – Drugs – Prevention 23. Tricyclic antidepressants, SNRIs, beta-blockers 24. Antiseizure and other orals – gabapentin, topiramate, candesartan, flunarizine 25. Onabotulinumtoxin 26. Gepants 27. Monoclonal antibody 28. Others: Magnesium, riboflavin, Coenzyme Q10, melatonin Part IV – Administration routes 29. Oral 30. Upper Nasal Space vs Traditional Nasal Spray 31. Inhaled 32. Sub/trans-cutaneous 33.I V/Infusion Part V – Alternative Management 34. The role of smartphone apps (DTx) 35. Traditional and herbal medicine 36. Chiropractic Therapy 37. Phototherapy 38. Nerve stimulators 39. Acupuncture 40 .Other ""mechanical"" techniques 41. Nutraceuticals 42. Mindfullness Part VI – Summary and conclusion [Shrewsbury] Final perspectives"

Reviews

Author Information

Dr. Stephen Shrewsbury recently left Impel Pharmaceuticals where he served as Chief Medical Officer (CMO) from March 2017 and led the development of Precision Olfactory Delivery of DHE through its clinical program and to FDA approval in September 2021. Formerly Stephen was CMO at MAP Pharmaceuticals where he conducted a successful clinical program for an inhaled version of DHE, but it never got approved due to manufacturing issues. Before MAP he was at Chiron Corporation where he was also on the International Pharmaceutical Aerosol Consortium Board of Science. Before Chiron, Stephen spent 9 years with GlaxoSmithKline (last 2 in the US) having moved into the industry in 1993 after 13 years working in the UK’s National Health Service. He has also been CMO for several other West Coast (US) biotech companies; has numerous patents; written and published a book, over 40 scientific papers and nearly 200 abstracts

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions